布鲁顿酪氨酸激酶抑制剂治疗B细胞肿瘤的研究进展(4)
[11] de Rooij MF， Kuil A， Geest CR， et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia [J]. Blood， 2012， 119(11)： 2590-2594.[12] Herman SE， Gordon AL， Hertlein E， et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 [J]. Blood ......
您现在查看是摘要页，全文长 2696 字符。